Table 1.
Patient characteristics
| Patient characteristics | All patients (n = 36) |
axSpA (n = 17) |
no axSpA (n = 19) |
p value |
|---|---|---|---|---|
| Age, Mdn (IQR) | 37.2 (20.6) | 34.4 (15.2) | 39.9 (18.0) | 0.24 |
| BMI, Mdn (IQR) | 24.6 (5.1) | 25.8 (2.3) | 24.4 (8.2) | 0.59 |
| Active smoker status, N (%) | 5 (13.9) | 4 (21.1) | 1 (5.9) | 0.34 |
| Female gender, N (%) | 21 (58.3) | 7 (41.2) | 14 (73.7) | 0.09 |
| Chronic lower back pain, N (%) | 36 (100) | 17 (100) | 19 (100) | 1.00 |
| Peripheral enthesopathy, N (%) | 10 (27.8) | 6 (35.3) | 4 (21.1) | 0.46 |
| Peripheral arthralgia | 15 (41.7) | 6 (35.3) | 9 (47.4) | 0.52 |
| Elevated baseline CRP, N (%) | 7 (38.9) | 4 (23.5) | 3 (15.8) | 0.68 |
| HLA-B27 positive, N (%) | 18 (50) | 10 (58.8) | 8 (42.1) | 0.51 |
| History of uveitis, N (%) | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| History of IBD, N (%) | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| History of psoriasis, N (%) | 1 (2.8) | 1 (5.9) | 0 (0) | 0.48 |
| NSAR response, N (%) | 27 (75) | 15 (88.2) | 12 (63.2) | 0.13 |
| Family history of axSpA | 7 (38.9) | 1 (5.9) | 6 (31.6) | 0.09 |
| Family history of IBD | 3 (8.3) | 0 (0) | 3 (15.8) | 0.23 |
| Family history of psoriasis | 4 (11.1) | 1 (5.9) | 3 (15.8) | 0.61 |
| Baseline PtGA, Mdn (IQR) | 5 (3) | 4 (3) | 5 (3) | 0.36 |
| Baseline Morning stiffness at T-1, Mdn (IQR) | 30 (51.3) | 30 (50) | 30 (37.5) | 0.86 |
| Baseline BASDAI, Mdn (IQR) | 4.2 (2.7) | 4 (2.3) | 4.3 (2.7) | 0.47 |
| BASMI > 0, N (%) | 13 (36.1) | 6 (35.3) | 7 (36.8) | 1.00 |
Statistical significances between the axSpA and non-axSpA patients were determined by Mann–Whitney U test for nominal variables and Fisher’s exact test for categorial variables
Mdn Median, IQR interquartile range, BMI body mass index, IBD inflammatory bowel disease, VAS visual analogue scale, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index